Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Psilocybin commercialization plans for treatment-resistant depression center on Compass Pathways' COMP360 and the practical build-out needed to deliver therapy at scale. Steve Levine explains that COMP360 durability in clinical results is a major commercial milestone, positioning the drug as a potential alternative to Spravato maintenance treatment patterns where relapse management is critical. The interview also focuses on operational infrastructure: site readiness, staffing, credentialing, and how label and REMS considerations affect rollout. Levine frames competition as time-dependent, expecting that sites prepared for COMP360 could also deliver shorter-acting competitors if they reach market. Additional discussion covers real-world effectiveness, potential label expansion, predicting responders, and how monotherapy versus adjunct use could shape launch geographies and competitive positioning.